{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:37:16Z","timestamp":1787020636413,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,14]],"date-time":"2024-01-14T00:00:00Z","timestamp":1705190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,14]],"date-time":"2024-01-14T00:00:00Z","timestamp":1705190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82173378"],"award-info":[{"award-number":["No. 82173378"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.82273463"],"award-info":[{"award-number":["No.82273463"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No.82173205"],"award-info":[{"award-number":["No.82173205"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chimeric antigen receptor CAR-T cell therapies have ushered in a new era of treatment for specific blood cancers, offering unparalleled efficacy in cases of treatment resistance or relapse. However, the emergence of cytokine release syndrome (CRS) as a side effect poses a challenge to the widespread application of CAR-T cell therapies. Melatonin, a natural hormone produced by the pineal gland known for its antioxidant and anti-inflammatory properties, has been explored for its potential immunomodulatory effects. Despite this, its specific role in mitigating CAR-T cell-induced CRS remains poorly understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, our aim was to investigate the potential of melatonin as an immunomodulatory agent in the context of CD19-targeting CAR-T cell therapy and its impact on associated side effects. Using a mouse model, we evaluated the effects of melatonin on CAR-T cell-induced CRS and overall survival. Additionally, we assessed whether melatonin administration had any detrimental effects on the antitumor efficacy and persistence of CD19 CAR-T cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our findings demonstrate that melatonin effectively mitigated the severity of CAR-T cell-induced CRS in the mouse model, leading to improved overall survival outcomes. Remarkably, melatonin administration did not compromise the antitumor effectiveness or persistence of CD19 CAR-T cells, indicating its compatibility with therapeutic goals. These results suggest melatonin's potential as an immunomodulatory compound to alleviate CRS without compromising the therapeutic benefits of CAR-T cell therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The study's outcomes shed light on melatonin's promise as a valuable addition to the existing treatment protocols for CAR-T cell therapies. By attenuating CAR-T cell-induced CRS while preserving the therapeutic impact of CAR-T cells, melatonin offers a potential strategy for optimizing and refining the safety and efficacy profile of CAR-T cell therapy. This research contributes to the evolving understanding of how to harness immunomodulatory agents to enhance the clinical application of innovative cancer treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-023-04779-z","type":"journal-article","created":{"date-parts":[[2024,1,14]],"date-time":"2024-01-14T17:01:48Z","timestamp":1705251708000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome"],"prefix":"10.1186","volume":"22","author":[{"given":"Na","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihao","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Dan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Lin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Hong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuli","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,14]]},"reference":[{"issue":"4","key":"4779_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69.","journal-title":"Blood Cancer J"},{"issue":"2","key":"4779_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jcyt.2019.12.004","volume":"22","author":"P Braendstrup","year":"2020","unstructured":"Braendstrup P, Levine BL, Ruella M. The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19. Cytotherapy. 2020;22(2):57\u201369.","journal-title":"Cytotherapy"},{"issue":"1","key":"4779_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N. Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47\u201362.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"4779_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen A, G\u00f6del P, Subklewe M, Stemmler HJ, Schl\u00f6\u00dfer HA, Schlaak M, Kochanek M, B\u00f6ll B, von Bergwelt-Baildon MS. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):1\u201314.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4779_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40164-020-00171-5","volume":"9","author":"Z Hao","year":"2020","unstructured":"Hao Z, Li R, Meng L, Han Z, Hong Z. Macrophage, the potential key mediator in CAR-T related CRS. Exp Hematol Oncol. 2020;9(1):1\u201312.","journal-title":"Exp Hematol Oncol"},{"issue":"6","key":"4779_CR6","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1182\/bloodadvances.2020003531","volume":"5","author":"JS Abramson","year":"2021","unstructured":"Abramson JS, Siddiqi T, Garcia J, Dehner C, Kim Y, Nguyen A, Snyder S, McGarvey N, Gitlin M, Pelletier C, et al. Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel-treated patients in the TRANSCEND NHL 001 trial. Blood Adv. 2021;5(6):1695\u2013705.","journal-title":"Blood Adv"},{"issue":"224","key":"4779_CR7","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, et al. Efficacy and toxicity management of 19\u201328z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224): 224ra225.","journal-title":"Sci Transl Med."},{"key":"4779_CR8","volume-title":"Melatonin: biosynthesis, physiological effects, and clinical applications","author":"H-S Yu","year":"2020","unstructured":"Yu H-S, Reiter RJ. Melatonin: biosynthesis, physiological effects, and clinical applications. Boca Raton: CRC Press; 2020."},{"issue":"9","key":"4779_CR9","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.3390\/nu12092561","volume":"12","author":"K Kleszczy\u0144ski","year":"2020","unstructured":"Kleszczy\u0144ski K, Slominski AT, Steinbrink K, Reiter RJ. Clinical trials for use of melatonin to fight against COVID-19 are urgently needed. Nutrients. 2020;12(9):2561.","journal-title":"Nutrients"},{"key":"4779_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106072","volume":"176","author":"A Ajoolabady","year":"2022","unstructured":"Ajoolabady A, Bi Y, McClements DJ, Lip GYH, Richardson DR, Reiter RJ, Klionsky DJ, Ren J. Melatonin-based therapeutics for atherosclerotic lesions and beyond: Focusing on macrophage mitophagy. Pharmacol Res. 2022;176: 106072.","journal-title":"Pharmacol Res"},{"issue":"6","key":"4779_CR11","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.arcmed.2018.12.004","volume":"49","author":"AL S\u00e1nchez-L\u00f3pez","year":"2018","unstructured":"S\u00e1nchez-L\u00f3pez AL, Ortiz GG, Pacheco-Moises FP, Mireles-Ram\u00edrez MA, Bitzer-Quintero OK, Delgado-Lara DLC, Ram\u00edrez-Jirano LJ, Vel\u00e1zquez-Brizuela IE. Efficacy of melatonin on serum pro-inflammatory cytokines and oxidative stress markers in relapsing remitting multiple sclerosis. Arch Med Res. 2018;49(6):391\u20138.","journal-title":"Arch Med Res"},{"issue":"2","key":"4779_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/jpi.12755","volume":"71","author":"X Chen","year":"2021","unstructured":"Chen X, Hao B, Li D, Reiter RJ, Bai Y, Abay B, Chen G, Lin S, Zheng T, Ren Y. Melatonin inhibits lung cancer development by reversing the Warburg effect via stimulating the SIRT3\/PDH axis. J Pineal Res. 2021;71(2): e12755.","journal-title":"J Pineal Res"},{"issue":"12","key":"4779_CR13","doi-asserted-by":"publisher","first-page":"21670","DOI":"10.1002\/jcp.28865","volume":"234","author":"R Shafabakhsh","year":"2019","unstructured":"Shafabakhsh R, Reiter RJ, Mirzaei H, Teymoordash SN, Asemi Z. Melatonin: a new inhibitor agent for cervical cancer treatment. J Cell Physiol. 2019;234(12):21670\u201382.","journal-title":"J Cell Physiol"},{"issue":"8","key":"4779_CR14","doi-asserted-by":"publisher","first-page":"12142","DOI":"10.1002\/jcp.28129","volume":"234","author":"MH Pourhanifeh","year":"2019","unstructured":"Pourhanifeh MH, Mahdavinia M, Reiter RJ, Asemi Z. Potential use of melatonin in skin cancer treatment: a review of current biological evidence. J Cell Physiol. 2019;234(8):12142\u20138.","journal-title":"J Cell Physiol"},{"key":"4779_CR15","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.omtn.2019.12.022","volume":"19","author":"MJ Hsieh","year":"2020","unstructured":"Hsieh MJ, Lin CW, Su SC, Reiter RJ, Chen AW, Chen MK, Yang SF. Effects of miR-34b\/miR-892a upregulation and inhibition of ABCB1\/ABCB4 on melatonin-induced apoptosis in VCR-resistant oral cancer cells. Mol Ther Nucleic Acids. 2020;19:877\u201389.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"7","key":"4779_CR16","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.3390\/ijms23073779","volume":"23","author":"L Wang","year":"2022","unstructured":"Wang L, Wang C, Choi WS. Use of melatonin in cancer treatment: where are we? Int J Mol Sci. 2022;23(7):3779.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"4779_CR17","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1016\/j.ymthe.2021.05.006","volume":"29","author":"B Webster","year":"2021","unstructured":"Webster B, Xiong Y, Hu P, Wu D, Alabanza L, Orentas RJ, Dropulic B, Schneider D. Self-driving armored CAR-T cells overcome a suppressive milieu and eradicate CD19+ Raji lymphoma in preclinical models. Mol Ther. 2021;29(9):2691\u2013706.","journal-title":"Mol Ther"},{"key":"4779_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-61779-080-5_20","author":"J Van Meerloo","year":"2011","unstructured":"Van Meerloo J, Kaspers GJ, Cloos J. Cell sensitivity assays: the MTT assay. Cancer Cell Cult Methods Protoc. 2011. https:\/\/doi.org\/10.1007\/978-1-61779-080-5_20.","journal-title":"Cancer Cell Cult Methods Protoc"},{"key":"4779_CR19","first-page":"634","volume":"17","author":"K Permpoonputtana","year":"2018","unstructured":"Permpoonputtana K, Tangweerasing P, Mukda S, Boontem P, Nopparat C, Govitrapong P. Long-term administration of melatonin attenuates neuroinflammation in the aged mouse brain. EXCLI J. 2018;17:634.","journal-title":"EXCLI J"},{"issue":"6","key":"4779_CR20","doi-asserted-by":"publisher","first-page":"11742","DOI":"10.3390\/ijms140611742","volume":"14","author":"G-J Lin","year":"2013","unstructured":"Lin G-J, Huang S-H, Chen S-J, Wang C-H, Chang D-M, Sytwu H-K. Modulation by melatonin of the pathogenesis of inflammatory autoimmune diseases. Int J Mol Sci. 2013;14(6):11742\u201366.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4779_CR21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/0471142735.im1401s111","volume":"111","author":"R Gon\u00e7alves","year":"2015","unstructured":"Gon\u00e7alves R, Mosser DM. The isolation and characterization of murine macrophages. Curr Protoc Immunol. 2015;111(1):14.","journal-title":"Curr Protoc Immunol"},{"issue":"12","key":"4779_CR22","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/s41419-022-05472-7","volume":"13","author":"H Li","year":"2022","unstructured":"Li H, Zeng C, Shu C, Cao Y, Shao W, Zhang M, Cao H, Zhao S. Laminins in tumor-derived exosomes upregulated by ETS1 reprogram omental macrophages to promote omental metastasis of ovarian cancer. Cell Death Dis. 2022;13(12):1028.","journal-title":"Cell Death Dis"},{"issue":"11","key":"4779_CR23","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651\u201368.","journal-title":"Nat Rev Immunol"},{"issue":"355","key":"4779_CR24","doi-asserted-by":"publisher","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","volume":"8","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi L-A, Berger C, Hudecek M, Pender B, Robinson E, Hawkins R, Chaney C, Cherian S, Chen X. Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor\u2013modified T cells. Sci Transl Med. 2016;8(355):355ra116-355ra116.","journal-title":"Sci Transl Med"},{"issue":"6","key":"4779_CR25","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis T, van der Stegen SJ, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell\u2013induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24(6):731\u20138.","journal-title":"Nat Med"},{"issue":"1","key":"4779_CR26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","volume":"8","author":"S Chen","year":"2023","unstructured":"Chen S, Saeed AF, Liu Q, Jiang Q, Xu H, Xiao GG, Rao L, Duo Y. Macrophages in immunoregulation and therapeutics. Signal Transduct Target Ther. 2023;8(1):207.","journal-title":"Signal Transduct Target Ther"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04779-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-023-04779-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04779-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T20:18:50Z","timestamp":1731010730000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-023-04779-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,14]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4779"],"URL":"https:\/\/doi.org\/10.1186\/s12967-023-04779-z","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,14]]},"assertion":[{"value":"4 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study adhered to the principles outlined in the Declaration of Helsinki and was approved by the institutional review board of Nanjing First Hospital, Nanjing Medical University. All of mouse experiments have been approved by the the Animal Care Committee of the Nanjing First Hospital, Nanjing Medical University and have been performed in accordance with relevant institutions and national guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}